Clinical study of high-dose ambroxol for treatment of acute exacerbations in chronic obstructive pulmonary disease
10.3760/cma.j.issn.0254-9026.2013.02.011
- VernacularTitle:大剂量沐舒坦治疗慢性阻塞性肺病急性加重期的临床研究
- Author:
Yong LI
;
Feng WU
;
Tingyan LIN
- Publication Type:Journal Article
- Keywords:
Ambroxol;
AECOPD;
Intravenous infusion
- From:
Chinese Journal of Geriatrics
2013;(2):162-164
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of high-dose ambroxol in treating acute exacerbations in chronic obstructive pulmonary disease (AECOPD).Methods The trial design was random,open,and parallel control.126 patients with AECOPD were involved.High-dose group received ambroxol 150 mg 3 times per day for 7 days (n=46),while conventional-dose group given ambroxol 30 mg 3 times per day for 7 days (n=40) and control group was given a routine treatment (antibiotic therapy,oxygen inhalation and bronchodilators) (n=40).Results The effective rates of high-dose group and conventional-dose group (95.6 %,77.5 %) were significantly higher compared with control group (55.0%) (x2 =19.81,4.53,both P<0.05).The average duration of hospitalization was significantly lower in high-dose group (10.78 ±0.95)d and conventional-dose group (11.75±0.84)d comparing with control group (13.15±0.89)d (q=11.88,7.24,both P<0.05).The clinical efficacy in high dose group was much better.Conclusions High-dose ambroxol is a safe and efficient therapy in the treatment of acute exacerbations in chronic obstructive pulmonary disease.